← Back to headlines
Biotech Firm Arcellx Acquired for $26 Million Amid Stock Underperformance and Competition
Biotech company Arcellx has been sold for $26 million, following a period of weak stock performance and increasing competition from rivals like Kelonia.
17 Feb, 18:07 — 17 Feb, 18:07
Sources
Showing 1 of 1 sources
Related Stories
US and Iran Resume Direct Military Strikes as Oil Prices Surge
20m ago
US Treasury Secretary Urges Bank of Japan to Maintain Sound Monetary Policy Amid Yen Volatility
2h ago
Apple Sets Executive Pay for New CEO John Ternus and Chair Tim Cook
2h ago
BOJ to debate rate rise, inflation much closer to 2% target: governor
2h ago